LAVA Therapeutics (LVTX) Competitors $1.34 +0.03 (+1.91%) Closing price 07/3/2025 01:00 PM EasternExtended Trading$1.33 -0.01 (-0.67%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LVTX vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLFShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Its Competitors Fate Therapeutics Kyverna Therapeutics Black Diamond Therapeutics Vaxart Lexeo Therapeutics Lyell Immunopharma BeyondSpring Neumora Therapeutics Nkarta FitLife Brands Fate Therapeutics (NASDAQ:FATE) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations. Does the media favor FATE or LVTX? In the previous week, Fate Therapeutics had 5 more articles in the media than LAVA Therapeutics. MarketBeat recorded 5 mentions for Fate Therapeutics and 0 mentions for LAVA Therapeutics. Fate Therapeutics' average media sentiment score of 0.55 beat LAVA Therapeutics' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Fate Therapeutics Positive LAVA Therapeutics Neutral Do insiders and institutionals have more ownership in FATE or LVTX? 97.5% of Fate Therapeutics shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by insiders. Comparatively, 9.5% of LAVA Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings & valuation, FATE or LVTX? LAVA Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M9.63-$186.26M-$1.49-0.77LAVA Therapeutics$11.98M2.93-$25.11M-$1.04-1.28 Do analysts prefer FATE or LVTX? Fate Therapeutics presently has a consensus price target of $3.83, suggesting a potential upside of 234.79%. LAVA Therapeutics has a consensus price target of $3.17, suggesting a potential upside of 137.20%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Fate Therapeutics is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13LAVA Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is FATE or LVTX more profitable? LAVA Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,318.93% -47.17% -34.60% LAVA Therapeutics N/A -86.38%-34.12% Which has more volatility & risk, FATE or LVTX? Fate Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. SummaryFate Therapeutics beats LAVA Therapeutics on 11 of the 16 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.72M$2.89B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-1.2821.7127.6320.25Price / Sales2.93281.07417.36118.60Price / CashN/A42.7336.8958.07Price / Book1.267.518.035.67Net Income-$25.11M-$55.14M$3.18B$249.21M7 Day Performance1.91%4.61%2.91%3.28%1 Month Performance2.69%4.72%3.72%5.55%1 Year Performance-29.37%5.92%35.14%21.08% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics1.8345 of 5 stars$1.34+1.9%$3.17+137.2%-25.8%$34.72M$11.98M-1.2860FATEFate Therapeutics4.1782 of 5 stars$1.14-4.2%$3.83+236.3%-63.8%$136.38M$13.63M-0.77550News CoverageAnalyst RevisionKYTXKyverna Therapeutics1.7319 of 5 stars$3.22+4.9%$18.50+474.5%-62.3%$132.68M$7.03M-0.9596BDTXBlack Diamond Therapeutics3.3047 of 5 stars$2.27-2.6%$14.60+543.2%-41.9%$132.49MN/A37.8390Positive NewsAnalyst UpgradeVXRTVaxart2.2841 of 5 stars$0.56-3.4%$3.00+435.3%-33.1%$132.42M$28.70M-2.08120LXEOLexeo Therapeutics1.9163 of 5 stars$3.96+1.3%$16.60+319.2%-70.2%$129.80M$650K-1.2058LYELLyell Immunopharma2.5997 of 5 stars$8.99+3.5%$20.00+122.5%-68.8%$128.68M$60K-0.36270BYSIBeyondSpringN/A$2.74-13.6%N/A-8.9%$127.80M$1.75M0.0080High Trading VolumeNMRANeumora Therapeutics2.5966 of 5 stars$0.75-5.1%$9.29+1,144.7%-91.7%$127.08MN/A-0.46108Gap UpNKTXNkarta2.269 of 5 stars$1.75-1.4%$14.33+721.4%-67.2%$125.60MN/A-1.16140FTLFFitLife Brands4.0641 of 5 stars$12.99-2.5%$20.50+57.8%-7.3%$125.09M$64.47M15.4620 Related Companies and Tools Related Companies Fate Therapeutics Alternatives Kyverna Therapeutics Alternatives Black Diamond Therapeutics Alternatives Vaxart Alternatives Lexeo Therapeutics Alternatives Lyell Immunopharma Alternatives BeyondSpring Alternatives Neumora Therapeutics Alternatives Nkarta Alternatives FitLife Brands Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LVTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
